163659-23-2

Upstream product

• 163659-25-4 (4R,1'S)-1-benzyl-4-(1-tert-butoxycarbonylamino)-2-pyrrolidone 
• 163659-22-1 1-benzyl-4-(R)-<1-(S)-ethyl>-2-pyrrolidone 
• 107259-14-3 4-acetyl-1-benzyl-2-pyrrolidinone 
• 104700-37-0 ethyl [L-(trans)]-4-[(t-butoxycarbonyl)amino]-2-pentenoate 
• 69619-25-6 ethyl (3RS,4S)-4-(tert-butoxycarbonylamino)-3-hydroxypentanoate 
• 117934-67-5 4-(1-aminoethyl)-1-benzyl-2-pyrrolidone 
• 107259-15-4 1-benzyl-4-(1-hydroxyiminoethyl)-2-pyrrolidone 
• 69619-23-4 ethyl (S)-4-[(tert-butoxycarbonyl)amino]-3-oxopentanoate 

Downstream Products

• 163659-25-4 (4R,1'S)-1-benzyl-4-(1-tert-butoxycarbonylamino)-2-pyrrolidone 
• 146981-10-4 7-[(R)-3-((S)-1-Amino-ethyl)-pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid 
• 163659-24-3 1-benzyl-3-(R)-(1-(S)-tert-butoxycarbonylaminoethyl)pyrrolidine 

Relevant academic research and scientific papers

Synthesis and structure-activity relationships of 7-[3-(1- aminoalkyl)pyrrolidinyl]- and 7-[3-1-aminocycloalkyl)pyrrolidinyl]-quinolone antibacterials

A series of 7-[3-(1-aminoalkyl and 1-aminocycloalkyl)-1- pyrrolidinyl]quinolones have been prepared and their biological properties evaluated. Among them, 1-(S)-aminoalkyl derivatives exhibited potent antibacterial activities against gram-positive and gram-negative organisms. They had moderate lipophilicity and high aqueous solubility compared to their aminomethyl counterparts; e.g., the 3-(1-aminoethyl)-1-pyrrolidinyl compound (83) showed superior pharmacokinetic properties to its aminomethyl counterpart (6).